Gemcitabine-Induced Thrombotic Microangiopathy Managed Conservatively in a Patient of Breast Cancer

Cureus. 2022 Aug 26;14(8):e28433. doi: 10.7759/cureus.28433. eCollection 2022 Aug.


Thrombotic microangiopathy (TMA) consists of a group of occlusive microvascular disorders, which include thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). TMA can be classified as primary or secondary based on the etiology. Gemcitabine-induced TMA is a rare side effect of the drug with varying clinical presentations. We present a case involving the classic triad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and renal failure associated with gemcitabine. Gemcitabine was immediately stopped, and our patient's condition improved with conservative management.

Keywords: anemia; chemotherapy; creatinine; gemcitabine; thrombocytopenia; thrombotic microangiopathy.

Publication types

  • Case Reports